Your dosage of Combivent will depend on the type of inhaler your healthcare provider has prescribed. With the old inhaler, two sprays are taken four times a day. With the new inhaler, one spray is taken four times a day. However, your healthcare provider may suggest that you take additional inhalations as needed to control your symptoms.
An Introduction to Dosing With Combivent
There is only one standard dosage of Combivent® (ipratropium and albuterol inhaler), regardless of your weight, age, or other medical conditions. As is always the case, do not adjust your dosage unless your healthcare provider specifically instructs you to do so.
In order to comply with the Montreal Protocol on Substances That Deplete the Ozone Layer, Combivent inhalers (in their original form) will not be available after July 2013 because they contain chlorofluorocarbons (CFCs), chemicals that deplete the ozone layer. A new formulation, Combivent Respimat, became available starting in October 2012. People using the old Combivent inhaler will need to get a new prescription in order to switch to the new Combivent Respimat inhaler.
Old Combivent Dosage for COPD
The recommended starting dose of Combivent for treating chronic obstructive pulmonary disease (COPD) is two sprays of Combivent four times a day. Your healthcare provider may recommend that you take additional doses as needed. However, you should not take more than 12 inhalations of Combivent in 24 hours.
New Combivent Respimat Dosage for COPD
The recommended starting dose of Combivent Respimat for treating chronic obstructive pulmonary disease (COPD) is one spray four times a day. Your healthcare provider may recommend that you take additional doses as needed. However, you should not take more than six inhalations of Combivent Respimat in 24 hours.
Food and Drug Administration, Center for Drug Evaluation and Research. Asthma and COPD inhalers that contain ozone-depleting CFCs to be phased out; alternative treatments available (4/13/2010). FDA Web site. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm208302.htm. Accessed April 16, 2010.
Boehringer Ingelheim Pharmaceuticals, Inc. FDA maintains essential use status of Combivent (ipratropium bromide and albuterol sulfate) Inhalation Aerosol through 2013 (4/13/2010). Boehringer Ingelheim Web site. Available at: http://us.boehringer-ingelheim.com/newsroom/2010/04-13-10_combivent_fda_ruling.html. Accessed April 16, 2010.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind.
Site users seeking medical advice about their specific situation should consult with their own physician. Click